Odevixibat

Ileal Bile Acid Transporter Inhibitor — ALIMENTARY TRACT AND METABOLISM

Key facts

Odevixibat is an onp drug in the Ileal Bile Acid Transporter Inhibitor class catalogued in DrugCentral. It was first approved by the EMA in 2021. Its mechanism of action is classified as Ileal Bile Acid Transporter Inhibitors. DrugCentral lists 2 molecular targets, including SLC10A2 and NR1H4. Recorded indications include Pruritus in progressive familial intrahepatic cholestasis (PFIC).

• Approval status: onp (first approved 2021 by the EMA).
• Drug class: Ileal Bile Acid Transporter Inhibitor.
• Mechanism of action: Ileal Bile Acid Transporter Inhibitors.
• Molecular targets: SLC10A2 and NR1H4 (2 listed in DrugCentral).
• Indications: Pruritus in progressive familial intrahepatic cholestasis (PFIC).
• ATC code: A05AX05 (Other drugs for bile therapy).
• Molecular formula: C37H48N4O8S2; molecular weight 740.95 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Pruritus in progressive familial intrahepatic cholestasis (PFIC)

Mechanism & targets

• Mechanism of action (MoA): Ileal Bile Acid Transporter Inhibitors
• Established pharmacologic class: Ileal Bile Acid Transporter Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Ileal sodium/bile acid cotransporter	SLC10A2	inhibitor	IC50 9.89
Bile acid receptor	NR1H4	unknown	IC50 9.80

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-07-20	FDA	—	ALBIREO PHARMA INC	Yes
2021-07-16	EMA	—	ALBIREO

ATC classification

ATC code	Therapeutic hierarchy
A05AX05	ALIMENTARY TRACT AND METABOLISM › BILE AND LIVER THERAPY › BILE THERAPY › Other drugs for bile therapy

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: ABCB11
• FDA label: ABCB11, ATP8B1
• FDA label: JAG1, NOTCH2
• HCSC label: ABCB11

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Liver transplant	104.4
Pruritus	79.7
Diarrhoea	72.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Odevixibat is on its molecule page.

• Molecular formula: C₃₇H₄₈N₄O₈S₂
• Molecular weight: 740.95 g/mol
• CAS number: —
• InChIKey: XULSCZPZVQIMFM-IPZQJPLYSA-N
• PubChem CID: 10153627

CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)N[C@H](C3=CC=C(C=C3)O)C(=O)N[C@@H](CC)C(=O)O)SC)C4=CC=CC=C4)CCCC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Odevixibat used for?

DrugCentral lists the following indications for Odevixibat: Pruritus in progressive familial intrahepatic cholestasis (PFIC).

How does Odevixibat work?

Odevixibat is classified as Ileal Bile Acid Transporter Inhibitors; its molecular targets in DrugCentral include SLC10A2 (inhibitor) and NR1H4.

When was Odevixibat first approved?

Odevixibat was first approved by the EMA in 2021.

What drug class does Odevixibat belong to?

Odevixibat is in the Ileal Bile Acid Transporter Inhibitor class.

What is the chemical formula of Odevixibat?

Odevixibat has the molecular formula C37H48N4O8S2 and a molecular weight of 740.95 g/mol.

Sources

• DrugCentral drug card 5468 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297588 — compound record and bioactivity
• PubChem CID 10153627 — chemical identifiers
• DrugBank DB16261 — drug record
• FDA UNII 2W150K0UUC — substance identity
• DailyMed: FDA labels for Odevixibat — current prescribing information (label search)
• UniProt Q12908 (SLC10A2) — target protein
• UniProt Q96RI1 (NR1H4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.